Know who does what.
Before you approve OEM supply.

A purchase order and a quality agreement answer different questions.

A purchase order records what you are ordering and the agreed commercial details. A quality agreement sets out responsibilities for defined quality activities and the communication between the parties. Linking them helps a buyer follow the project without expecting one document to answer every question.

FDA's quality-agreement guidance concerns contract drug manufacturing. It recommends keeping quality agreements separate, or separable, from commercial contracts, and distinguishing quality responsibilities from matters such as prices and delivery terms. Read the FDA guidance, section IV.A (PDF).

That pharmaceutical reference provides useful terminology. It does not establish that a Wholesale Lab Peptides order is a medicine, approved API or GMP-certified project. The worksheet below is a discussion aid for an enquiry, not an issued agreement or a substitute for the parties' reviewed documents.

For the commercial comparison itself, use the wholesale quote guide. Use this page to identify the people and handovers behind the proposed order.

Start with the actual work, then assign a responsible contact.

List the proposed activities before adding company names: material supply, any agreed testing, label design, printing, packing, document review and dispatch coordination. Confirm which activities are actually included in the quotation. An OEM brand name on the carton does not identify every organisation involved.

Use the named business and contact for each activity, with a backup contact where appropriate. Ask who prepares the record and who reviews it. If a supplier coordinates an outside laboratory or printer, clarify the handover and the records you will receive. Do not assume an outside party or testing service is involved unless it is confirmed.

ICH Q10 section 2.7 describes suitability assessment, written responsibilities and communication, and subsequent monitoring for outsourced activities in a pharmaceutical quality system. Read ICH Q10 section 2.7 (PDF). Here, the practical question is whether each proposed step has an agreed owner and a traceable response.

Turn “we handle everything” into reviewable handovers.

Fill the sheet with confirmed answers rather than assumed duties. A blank contact or an unspecified record is an open item. Mark the person who will close it and the point in the project when an answer is needed. The table does not promise that a service or document is available.

One agreed document set can still contain several different order lines.

A BPC-157 vial enquiry, a Semax presentation and a GHK-Cu private label project each need an identifiable specification reference. Keep material names and presentations on separate order lines where the requirements differ. A shared branding brief should not merge the technical descriptions.

For a GLOW or KLOW blend enquiry, keep unresolved identities, component amounts and totals on the open-question list. Approval of a carton design does not resolve an unanswered blend specification. Wholesale strengths, pack contents and defined kit configurations are confirmed during enquiry; this checklist introduces no new catalogue amount or formulation.

Connect each line with the bulk order specification brief and its relevant document review. The responsibility sheet then records who supplies and reviews those references, without copying every technical field into the agreement.

An artwork approval is a specific decision.

Imagine an OEM buyer approves the logo placement on a proposed vial label. The peptide name still needs checking against the material brief, and the lot-related fields have not yet been populated. Record the design approval for the version reviewed, with the remaining checks visible.

Later, a populated print proof and a document index are supplied. Those are separate handovers with separate review questions. Recording them separately prevents an early design sign-off from being read as acceptance of every later detail.

Apply the same approach to a pen-style kit: identify whether the review covers the outside carton, the defined contents, the component artwork or another stated item. Use the kit carton proof checklist and packaging bill of materials for those detailed reviews.

Give an unexpected document or change a clear route back.

Agree a contact path for a missing report, inconsistent identifier or proposed replacement component. Record the question, the affected order line, the person asked to respond and the document version being discussed. Keep the answer with the original question so another reviewer can follow the decision.

A repeat order should point to the applicable versions rather than relying on “same as last time.” The reorder change review covers the comparison. If a reported result misses an agreed criterion, the OOS follow-up guide provides a separate investigation checklist.

Keep the quality discussion connected to the commercial record. An updated drawing, a new document request or an open specification question may need a corresponding quotation revision. The parties can then see what has been agreed and what still needs a response before the next step.

Bring the product brief and responsibility questions together.

Send the peptide names, required quantity, vial or defined pen-style kit presentation and destination in the USA, Canada or Australia. Add the branding work requested and the records your reviewer needs. Identify the contact who can approve artwork and answer specification questions.

Wholesale Lab Peptides has warehouses in the USA, Canada, Australia and Hong Kong. Confirm current local availability and dispatch arrangements for the selected order. Discuss the proposed services and document handovers before treating any worksheet as an accepted project arrangement.

Browse the wholesale catalogue, review OEM and private label options or email sales@wholesalelabpeptides.com with the open questions.